Exclusive Summary

• **Best-in-Class Potential**: Head-to-head Phase III trials demonstrate superior efficacy over Paxlovid, with faster median viral clearance (8.4 days vs. 9.5 days) and 7-10x better in vitro IC50 potency.
• **Optimized Safety & Dosage**: Achieves therapeutic effect at a significantly lower daily dose (300 mg) compared to competitors (600 mg–1500 mg), reducing manufacturing costs and potential toxicity while maintaining efficacy against XBB variants.
• **Global Expansion & New Indications**: Currently undergoing Oxford-led international trials (PLATCOV), with distinct commercial potential in veterinary markets (Feline Infectious Peritonitis) and Long COVID treatments.

Asset Materials

Contact Us for Full Materials